Genome-wide association analysis of susceptibility and clinical phenotype in multiple sclerosis by Baranzini, Sergio E. et al.
Genome-wide association analysis of susceptibility
and clinical phenotype in multiple sclerosis
Sergio E. Baranzini1,{, Joanne Wang1,{, Rachel A. Gibson2,{, Nicholas Galwey2, Yvonne
Naegelin3, Frederik Barkhof4, Ernst-Wilhelm Radue5, Raija L.P. Lindberg3, Bernard M.G.
Uitdehaag6, Michael R. Johnson2,7, Aspasia Angelakopoulou2, Leslie Hall2, Jill C. Richardson2,
Rab K. Prinjha2, Achim Gass5, Jeroen J.G. Geurts4, Jolijn Kragt6, Madeleine Sombekke6, Hugo
Vrenken8, Pamela Qualley1, Robin R. Lincoln1, Refujia Gomez1, Stacy J. Caillier1, Michaela
F. George1, Hourieh Mousavi1, Rosa Guerrero1, Darin T. Okuda1, Bruce A. C. Cree1, Ari J.
Green1, Emmanuelle Waubant1, Douglas S. Goodin1, Daniel Pelletier1, Paul M. Matthews2,7,
Stephen L. Hauser1, Ludwig Kappos3, Chris H. Polman4 and Jorge R. Oksenberg1,
1Department of Neurology, University of California, San Francisco, USA, 2R&D, GlaxoSmithKline, UK and USA,
3Department of Neurology, University Hospital Basel, University of Basel, Switzerland, 4Department of Radiology,
Vrije Universiteit Medical Centre, Amsterdam, The Netherlands, 5Department of Neuroradiology, University Hospital
Basel, University of Basel, Switzerland, 6Department of Neurology, Vrije Universiteit Medical Centre, Amsterdam, The
Netherlands, 7Department of Clinical Neurosciences, Imperial College, London, UK and 8Department of Physics and
Medical Technology, Vrije Universiteit Medical Centre, Amsterdam, The Netherlands
Multiple sclerosis (MS), a chronic disorder of the central nervous system and common cause of neurological
disability in young adults, is characterized by moderate but complex risk heritability. Here we report the
results of a genome-wide association study performed in a 1000 prospective case series of well-characterized
individuals with MS and group-matched controls using the Sentrixw HumanHap550 BeadChip platform from
Illumina. After stringent quality control data filtering, we compared allele frequencies for 551 642 SNPs in 978
cases and 883 controls and assessed genotypic influences on susceptibility, age of onset, disease severity,
as well as brain lesion load and normalized brain volume from magnetic resonance imaging exams. A multi-
analytical strategy identified 242 susceptibility SNPs exceeding established thresholds of significance,
including 65 within the MHC locus in chromosome 6p21.3. Independent replication confirms a role for
GPC5, a heparan sulfate proteoglycan, in disease risk. Gene ontology-based analysis shows a functional
dichotomy between genes involved in the susceptibility pathway and those affecting the clinical phenotype.
INTRODUCTION
Multiple sclerosis (MS) is a chronic and often disabling neuro-
logical disease associated with inflammation, loss of myelin
and ensuing axonal damage in the central nervous system
(CNS) (1). It is a relatively common disease, affecting
approximately 1–2 per 1000 individuals; ancestry, latitude,
sex, and age influence risk and incidence (2,3). Etiologically,
MS is characterized by a polygenic heritable component that
involves multifaceted interactions with environmental factors
(4). Two genes, HLA-DRB1 and IL7R (CD127), have been
unambiguously associated with disease susceptibility and/or
protection following their identification as candidates by func-
tion (5–9). Additional disease genes were discovered through
genome-wide association analysis (10,11), most notably the
independently replicated IL2RA (CD25), CD58 (LFA3),
CLEC16A (KIAA0350) and EVI5 (12–15), demonstrating the
power of this approach to identify even the modest genetic
effects that contribute to this complex neurological trait.
Clinical manifestations of MS are diverse and vary from
benign to a rapidly evolving and ultimately incapacitating
disease. Concordance in families for some early and late
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clinical features suggests that in addition to susceptibility,
genomic variants influence disease severity or other aspects
of the phenotype (16–19). It has been difficult to discern,
however, whether phenotypic diversity reflects true etiological
heterogeneity (20), modifying roles of specific genes (19), or
some combination of the two. Unfortunately, published
reports proposing specific genetic influences on the natural
history of MS relied almost exclusively on small series of
cases, retrospective clinical assessment and, in some cases,
non-validated phenotypic endpoints. Furthermore, the con-
founding effects of drug treatment and population stratification
have not been generally considered. It is also important to
recognize that the aggregate contribution of individual germ
line variants to the disease course may be quite modest. This
is highlighted by observations that the clinical expression of
MS can be different between monozygotic twin siblings.
Nevertheless, the demonstration of even a modest genetic
effect of a known gene on the course of MS could help eluci-
date fundamental mechanisms of disease expression and yield
a major therapeutic opportunity.
To identify additional common variants associated with MS
risk and phenotype, we conducted a genome-wide association
study (GWAS) using the Sentrixw HumanHap550 BeadChip
platform from Illumina in a 1000 prospective case series of
well-characterized individuals with MS and matched controls.
After stringent quality control, we compared allele frequencies
for 551 642 SNPs in 978 cases and 883 controls and assessed
genotypic influences on susceptibility, age of onset, disease
severity, brain lesion load and normalized brain volume.
RESULTS
A total of 2068 individuals were enrolled within a 12 month
period and genotyped using the Illumina Sentrixw Human-
Hap550 BeadChip platform. Following quality control filter-
ing of SNPs and samples, the final dataset included 978 MS
cases and 883 controls of European ancestry. Approximately,
half of these were enrolled by the US site, with one-quarter
from each of the two European sites. To assess bias introduced
by population stratification, the entire dataset and each case–
control group were scanned for the presence on non-random
distribution of alleles using STRUCTURE (v.2.) (21) and prin-
cipal component analysis (data not shown). This analysis
resulted in the exclusion of 36 individuals (15 cases and 21
controls) enrolled at the US site and three cases from the
EU sites. We then assessed the median distribution of test
statistics with the genomic control parameter lGC (22):
San Francisco lGC ¼1.03, Basel l GC ¼1.02, Amsterdam l
GC ¼1.01; all sites combined, l GC ¼1.04. The results show
that the variance inflation factors due to subpopulation struc-
ture within each cohort are less than 3%, and the pooled vari-
ance inflation factor is still less than 4%. In any case, origin of
the sample was entered into the logistic regression model as a
covariate to minimize the effects of the pooled variance
inflation.
Table 1 lists demographic and clinical features of the study
subjects. Overall, there was a high degree of demographic simi-
larity among samples from the three sites, including frequency
of HLA-DRB11501 carriers, but significant differences
among sites were noted for some of the clinical variables
used in the analysis of genotype–phenotype correlations. For
all analyses, samples were pooled into a single dataset to
increase statistical power (23).
Figure 1 shows the genome-wide trend association results.
As expected, the strongest association signal observed in this
experiment was in the MHC region in chromosome 6p21.
Q–Q plots of the association results are shown in Figure 2.
P-values without adjustment for gender, DRB11501 and
site of sample origin, and the corresponding P-values with
adjustment, are plotted for all SNPs as a function of the null
distribution, showing an excess in the tail of the distribution
at P, 1  1023 (without adjustment) and P , 1  1024
(with adjustment). Following adjustment, the most extreme
P-values are still smaller than expected, consistent with the
presence of true genetic associations. P-values for SNPs in
the HLA region are highlighted, showing that without adjust-
ment, the SNPs from this region are concentrated among the
low P-values, whereas with adjustment, they are distributed
over the full range of P-values. Logistic regression analysis
of these case–control data after adjusting for gender, site
and DRB11501 identified 242 SNPs with P  1  1024,
including 65 within the MHC locus (Supplementary Material,
Table S1.1).
The top peak SNPs located in the MHC class-II sub-region;
rs3129934 (2Log10(P) 32.58) in the intron 3/4 of C6orf10, at
the telomeric edge of the class II region, between BTNL2 and
NOTCH4, rs9267992 (2Log10(P) 32.00) adjacent (telomeric)
to LOC401252, rs9271366 (2Log10(P) 30.00) in the inter-
genic region between HLA-DRB1 and HLA-DQA1, and
rs3129860 adjacent (telomeric) to HLA-DRA (Fig. 3A). It is
likely that these signals reflect linkage disequilibrium (LD)
with the well-established risk allele HLA-DRB11501,
although following adjustment for gender and site, and upon
conditional analysis for DRB11501, there is a residual
effect in C6orf10 (2Log10(P) 4.00). The adjusted data also
suggest the presence of independent association in the HLA-
class I region (Fig. 3B), consistent with recent studies report-
ing multiple autonomous susceptibility signals in the locus
(24,25). The top secondary signals are localized around
TRIM 26, TRIM 15 and TRIM 10 members of the tripartite
motif (TRIM) gene family. Although their functions are
unknown, the presence of a RING domain suggests DNA-
binding activity.
Results for the non-HLA SNPs showing the strongest evi-
dence of association (threshold of P  1025) are shown in
Table 2. These include 13 SNPs in eight chromosomes. Of
special interest is the identification of Glypican5 (GPC5,
13q32), a heparan sulfate proteoglycan for which an
IFNb-associated pharmacogenomics role in MS was recently
suggested (26). Also noteworthy are Tribbles Homolog 2
(TRB2) in 2p25.1-p24.3, a putative autoantigen in uveitis
(27), and CUB and sushi multiple domains 1 (CSMD1) in
8p23.2, a complement regulatory protein highly expressed in
the CNS (28). It is of interest to note that CMSD1 is located
within a genomic region with a remarkable high mutation
rate and as a consequence, is highly diverse between
humans and non-human primates (29).
Another gene of outstanding interest emerging from this
scan is the aminophospholipid transporter (APLT), class I,
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type 8A, member 1 (ATP8A1), a member of a family of pro-
teins driving uphill transport of ions across membranes.
ATP8A1 also transports phosphatidylserine, a phospholipid
component of myelin shown to be increased in the experimen-
tal autoimmune encepahlomyelitis brain, affecting the fluidity
and integrity of the myelin sheath (30,31). In addition, phos-
phatidylserine on the surface of apoptotic cells serves as mol-
ecular addresses for the T-cell immunoglobulin mucin proteins
for the effective clearance of apoptotic cells and prevention of
autoimmunity (32).
Stratification by gender revealed additional genes of interest
(Supplementary Material, Tables S1.2 and 1.3); 112 in the
females only group, (39 intersecting with the all group and
none with the males only group) and 60 in the males only
group (nine intersecting with the all group). Some noteworthy
examples include Tankyrase (TNKS) in females, a poly
(ADP-ribose) polymerase associated with telomere length
control and implicated in the regulation of EBV origin of
plasmid replication (33), the prostaglandin receptor EP4
(PTGER4) in females, a gene recently associated with
Crohn’s disease (34), and the gamma-aminobutyric acid
(GABA) A receptor beta 3 (GABRB3) in males, a gene
coding for a subunit of a chloride channel that serves as the
receptor for the gamma aminobutyric acid, a major inhibitory
transmitter in the CNS and associated with Angelman syn-
drome, Prader–Willi syndrome and autism (35,36).
In order to overcome the potential bias for detection of
false-positive associations in large genes with particularly
dense SNP coverage, we applied the Sˇida´k correction to the
gene-wise minimum P-value. For each statistical and genetic
model fitted to the case–control phenotype, values of Pmin
without correction and Pmin, corrected, adjusted were obtained
for 18 551 genes annotated in the Illumina array (counting
different splice variants as different genes). The correlations
among these gene-based measures of association are mode-
rately strong (Supplementary Material, Table S2). The genes
showing the strongest associations for each measure are, there-
fore, presented in Supplementary Material, Tables S3.1–3.4.
The top MHC secondary signals (TRIM 26, TRIM 15 and
TRIM 10) were also detected by the Sˇida´k-corrected
minimum P-value analysis of the data (Supplementary
Material, Table S3). Outside chromosome 6p21, a group of
genes located in chromosome 20p13 displayed robust associ-
ation, including C20orf46, PSMF1 (Proteasome inhibitor
subunit 1), SDCBP2 (Syndecan binding protein 2, or Syntenin)
and SNPH (Syntaphylin or Synaptobrevin). The three top
Table 1. Summary of demographic and clinical characteristics of study participants at the three sites at time of analysis
Variable Total San Francisco Amsterdam Basel
Patients Controls Patients Controls Patients Controls Patients Controls
Female, n (%) 653 (67) 584 (66) 334 (69) 287 (66) 137 (60) 148 (62) 182 (69) 149 (71)
Male, n (%) 325 (33) 299 (34) 153 (31) 147 (34) 92 (40) 90 (38) 80 (31) 62 (29)
Female:Male ratio 2.0:1 2.0:1 2.2:1 2.0:1 1.5:1 1.6:1 2.3:1 2.4:1
Age at onset of disease, mean (range) 34 (11–61) 34 (11–61) 35 (16–60) 32 (11–59)
Age at time of analysis, mean (range) 47 (21–69) 46 (21–74) 46 (21–69) 46 (23–69) 48 (25–67) 45 (24–68) 47 (21–69) 47 (21–74)
DRB11501þ individuals, n (%) 474 (48) 190 (22) 224 (46) 86 (20) 118 (52) 59 (25) 132 (50) 45 (21)
Disease duration (years) mean 11.5 10.7 11.4 12.9
Median (range) 9.0 (0–47) 8.0 (0–46) 10.0 (1–34) 11.0 (0–47)
Disease type, n (%)
Relapsing remitting 659 (67.9) 343 (70.4) 141 (61.8) 175 (68.4)
Secondary progressive 137 (14.1) 46 (9.5) 46 (20.2) 45 (17.5)
Primary progressive 72 (7.4) 18 (3.7) 29 (12.7) 25 (9.8)
Clinical isolated syndrome 100 (10.3) 79 (16.2) 10 (4.4) 11 (4.3)
Unknown 3 (0.3) 1 (0.2) 2 (0.9) 0 (0)
DMT, n (%)a 432 (54) 245 (63) 60 (32) 127 (58)
EDSS, n (%)b
,3 440 (55.4) 279 (71.9) 58 (31.0) 103 (47.0)
3 to ,6 271 (34.1) 86 (22.2) 95 (50.8) 90 (41.1)
6–6.5 68 (8.6) 22 (5.7) 24 (12.8) 22 (10.1)
7 15 (1.9) 1 (0.3) 10 (5.4) 4 (1.8)
Mean (SD) 2.74 (1.81) 2.06 (1.64) 3.74 (1.72) 3.07 (1.67)
MSSS, nc 794 388 187 219
Median 2.97 2.23 4.82 3.17
Mean (SD) 3.45 (2.37) 2.70 (2.21) 4.81 (2.23) 3.61 (2.21)
T2 lesion load/mm3, nd 791 387 185 219
Median 2580 2164 3001 3276
Range 0–81317.2 0–64258.3 0–81317.2 0–34984.5
nBPV/cm3, ne 753 371 176 206
Mean (SD) 1530.8 (86.11) 1511.6 (81.91) 1554.5 (83.17) 1544.9 (88.55)
Range 1225–1767 1225–1704 1360–1750 1309–1767
aDisease modifying treatment (DMT). Test of association with site: x2 ¼ 50.64; P , 0.0001.
bExpanded disability status scale (EDSS). Test of association with site: x2 ¼ 102.17; P , 0.0001.
cMultiple sclerosis severity scale (MSSS). Test of variation among sites (Kruskal–Wallis test): x2 ¼ 107.82; P, 0.0001.
dT2 lesion load/mm3. Test of variation among sites (Kruskal–Wallis test): x2 ¼ 18.84; P , 0.0001.
eNormalized brain parenchymal volume (nBPV). ANOVA of variation among sites: F ¼ 19.77; P, 0.0001.
a–e analyses include only subjects with relapsing remitting and secondary progressive disease.
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non-HLA hits identified in the screening, C20orf46, GPC5 and
PCZRN4 (Table 2) survived this correction although GPC5
and PCZRN4 ranked lower than the genes mentioned above
(Supplementary Material, Tables S3.1–3.4).
Given the lack of full-scale independent replication, these
results were considered with caution. To add confidence to
the associations reported here, we compared the results of
the present analysis with those reported by the International
Multiple Sclerosis Genetics Consortium (IMSGC) (11).
SNPs showing support for association in both studies
(thresholds P , 1024) are shown in Table 3. R2 values
between the SNPs in the different studies are, however, very
low. Nevertheless, the joint association of PARK2 (P ¼
0.0004), coding for an E3 ubiquitin ligase, is of interest
because of a demonstrated role in Parkinson disease (37).
Insofar genes reported by the Consortium and validated by
others (11–15), a SNP within CD58 (rs1335532) ranked
16 094th (2.9 percentile) in the current study. The IMSGC
SNP (rs12044852) was not represented in the Illumina plat-
form, but according to HapMap data, both SNPs map to
intron 10/11 and are in high LD (R2 ¼ 0.93) (Table 4). This
indicates high concordance in the results of both studies and
suggests that resequencing the flanking exons may identify a
functional causative polymorphism in CD58. IL7R ranked
10 167th in this study (1.8 percentile). The exon 6 SNP
rs6897932 is represented in both platforms and provides the
strongest association in both studies, further supporting a func-
tional role in disease susceptibility (8). The top IL2RA SNP in
this study (rs11256497) ranked 7230th (1.3 percentile).
Similar to the IMSGC top SNP (rs12722489), it is located in
intron 1/2 but they are in relatively low LD (R2 ¼ 0.11). On
the other hand, rs12722515 in this study, also in intron 1/2
is in high LD (R2 ¼ 0.93) and confers an OR ¼ 1.21, but
ranks 95 421th, suggesting allelic heterogeneity and that the
causative variants may be located in the 50 region of the
gene. The best CLEC16A SNP in the current study was
rs11074952 in intron 21/22 and ranked 1020 (0.18 percentile).
This SNP is in weak LD with the IMSGC SNP rs28087 in
intron 22/23 (R2 ¼ 0.24). In this study, the most tightly corre-
lated SNP with the IMSGC is rs42369 (R2 ¼ 0.71), but shows
no association ranking 113 789th, indicating the need for
additional fine mapping of this intriguing gene. All the
Figure 1. GWA trend test scan. Genome-wide association results for 551 642 SNPs in 978 MS cases and 883 controls using a linear trend test for additive
allelic effects on disease penetrance (Cochran–Armitage trend test). As expected, the strongest association signal was located in the MHC region in chromo-
some 6p21.
Figure 2. Q–Q plot distribution of the GWAS association results. P-values
adjusted for HLA-DRB11501 and gender (A, trend test; B, genotypic test)
are plotted for all SNPs as a function of the null distribution showing an
excess in the tail of the distribution at P , 1  1024. Red line is equal to
expectation on H0. Grey/light green, P-values without adjustment for the
HLA-DRB1 locus. Black/bright green, P-values with adjustment by including
HLA-DRB1 as a covariate in the model. Green (light or bright), SNP loci in
HLA region; black/grey, other SNPs.
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top-associated IMSGC SNPs are within the 3.0 percentile of
markers in this study. On the other hand, the top EVI5
marker in this study (rs10747446, intron 10/11) is in high
LD (R2 ¼ 0.92) with the IMSGC SNP (rs92833128, intron
10/11), but is not significantly associated and ranks 83 341th.
SNP rs7321717, located approximately 1240 kb from GPC5,
showed a PTD P-value of 0.0004 in the IMSGC study. The
metrics of LD between rs9523762 (this study) and
rs7321717 (IMSGC) in GPC5 is 0.00014 (R2) and 0.01189
(D0). We followed the GPC5 data by genotyping 3 SNPs in
an independent MS group consisting 974 affected individuals,
recruited in the US using identical inclusion criteria. This
dataset was compared to the control group used in the original
screen generating robust evidence of replication when gender
and HLA-DRB11501 status were included in the logistic
regression model (Table 5).
Next, we performed a comprehensive statistical analysis to
seek genome-wide associations with phenotypes related to the
expression of MS. This analysis was restricted to individuals
diagnosed as relapsing remitting or secondary progressive
MS (N ¼ 794) to limit the potential confounding influence
of disease heterogeneity. Using regression analysis on the
combined data from the three sites, and of data from each
site separately with subsequent combination of the P-values
by the Fisher’s method, a number of allelic variants were mod-
estly associated with the different phenotypic traits selected
for this study (Supplementary Material, Tables S4–S7).
Table 6 displays the top (P , 1025) markers associated with
the following phenotypic endpoints: age of onset, multiple
sclerosis severity scale (MSSS), brain parenchymal volume
(nBPV) and T2 lesion load.
In order to explore the potential functionality of the associ-
ated SNPs across phenotypes, we conducted a gene ontology
(GO) analysis of the most significant markers to assess enrich-
ment in any of the pre-defined functional categories (Biologi-
cal process, molecular function and cellular component) using
a GO tree machine (Vanderbilt University) (Table 7). In this
analysis, we included genes containing at least one SNP
with a P-value ,1  1024 for each of the traits (Supplemen-
tary Material, Tables S1.1, 4–7). To avoid redundancy, only
Figure 3. Association and logistic regression analyses of the extended MHC region. Results of allelic tests of association (top panel) and results of subsequent
logistic regression analyses conditioning upon HLA-DRB11501 (bottom panel).
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the most specific of any given set of nested significant GO cat-
egories is reported. Antigen processing and presentation were
among the most significantly enriched GO categories for
disease susceptibility, together with, surprisingly, CNS devel-
opment. On the other hand, neural processes including axon
guidance and glutamate signaling were over-represented in
Table 2. Top (non-HLA) markers associated with susceptibility, 2Log10(P) 5.0
SNP Chrom Position GeneSymbol Alleles Minor allele
frequency
Odds ratio Adj Geno
Log P-valuea
Adj Trend
Log P-valueb
rs397020 20 1153886 C20orf46 A/G 0.484 0.711 6.097 6.102
rs9523762 13 92129887 GPC5 A/G 0.346 1.361 5.155 5.921
rs1458175 12 40252128 PDZRN4 G/T 0.486 1.342 5.102 5.770
rs1529316 8 3815546 CSMD1 C/T 0.468 1.356 4.921 5.699
rs2049306 8 3819488 CSMD1 A/C 0.495 1.362 4.796 5.585
rs908821 3 142023416 SLC25A36 C/T 0.285 0.732 4.854 5.538
rs1755289 9 17928351 SH3GL2 C/T 0.389 0.739 5.041 5.523
rs16914086 9 98068032 TBC1D2 A/G 0.115 0.886 5.252 1.161
rs651477 2 119111921 EN1 A/G 0.263 1.378 4.699 5.143
rs7672826 4 182774844 MGC45800 A/G 0.341 1.366 4.886 5.102
rs1841770 3 149239384 ZIC1 G/T 0.470 0.746 4.310 5.076
rs1109670 2 9200636 DDEF2 A/C 0.256 1.381 4.000 5.046
rs7607490 2 12801718 TRIB2 A/G 0.115 1.558 4.000 5.013
aGenotypic test of association (the logistic regression model, adjusted for covariates).
bTrend test for association (the logistic regression model, adjusted for covariates).
Table 3. Top (non-HLA) susceptibility markers overlapping between the current and IMSGC studies
SNP Chrom Position Gene Alleles Odds ratio Adj Geno
Log P-valuea
Adj Trend
Log P-valuea
PTDT
Log P-valueb
HapMap R2
rs11582200a 1 29810973 PTPRU A/C 1.256 4.00 2.51 – 0.0001
rs4949238b 1 30091689 PTPRU A/C 1.376 – – 3.17
rs2144208a 6 162020735 PARK2 A/G 0.824 4.00 1.95 – 0.01
rs9458281b 6 161869691 PARK2 T/C 0.706 – – 3.40
rs10283372a 8 74498045 RDH10 C/T 1.146 4.72 0.94 – 0.02
rs4738350 b 8 74478622 RDH10 A/G 0.469 – – 3.40
rs2096735a 11 96368652 JRKL C/T 1.151 4.00 1.27 – 0.0001
rs1941861b 11 97548590 JRKL A/G 1.396 – – 3.00
rs10140464a 14 48280389 RPS29 A/G 0.707 4.00 4.68 – 0.0001
rs10483556b 14 49029992 RPS29 G/A 0.740 – – 2.89
aTop SNP in current study.
bTop SNP in IMSGC study (11).
Table 4. Performance of independently replicated IMSGC (non-HLA) Susceptibility markers in the current study
SNP Chrom Position Gene Alleles Odds ratio Adj Geno
Log P-valuea
Adj Trend
Log P-valuea
PTDT
Log P-valueb
HapMap
R2
rs10747446a,c 1 92820423 EVI5 A/G 1.00 0.99 0.12 – 0.92
rs10735781b 1 92833128 EVI5 C/G 1.29 – – 3.65
rs1335532a,c 1 116812999 CD58 C/T 0.78 1.53 1.78 – 0.93
rs12044852b 1 116799821 CD58 T/G 0.68 – – 3.00
rs6897932a,c 5 35910332 IL7R C/T 1.21 1.48 2.00 – –
rs6897932b 5 35910332 IL7R T/C 0.81 – – 2.23
rs11256497a 10 6127800 IL2RA A/G 1.17 1.87 2.15 – 0.11
rs12722489b 10 6142018 IL2RA T/C 0.74 – – 2.88
rs12722525c 10 6121236 IL2RA G/T 1.21 0.69 0.93 – 0.93
rs11074952a 16 11126107 CLEC16A A/G 0.80 2.59 3.10 – 0.24
rs28087b 16 11160330 CLEC16A G/A 1.16 – – 1.56
rs42369a 16 11172113 CLEC16A A/G 0.91 0.47 0.84 – 0.71
aTop SNP in current study.
bTop SNP in IMSGC study (11).
cMost tightly correlated SNP in current study with top IMSGC SNP.
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phenotypes directly related to CNS damage (i.e. T2 lesion load
and brain volume, respectively). Cellular mechanisms were
primarily represented in time-dependent processes such as
MSSS and age of onset.
DISCUSSION
We report the largest GWAS performed so far in a deeply phe-
notyped MS dataset. The recently reported IMSGC study
screened 931 trios with 334 923 SNPs (11). Here we used a
case–control design (n ¼ 978 versus 883) with higher SNP
density (551 642 SNPs). In contrast to the IMSGC study,
which included a second replication stage of top susceptibility
hits and candidate genes, the emphasis of this study was to
isolate both, disease risk and modifiers. The present scan has
identified a number of novel non-HLA candidate genes associ-
ated both with susceptibility and with clinical manifestations
of the disease. As expected, each significant association has
a very modest effect and reflects a small share of the genetic
variance affecting MS risk and progression.
Among the most interesting association results is the glypi-
can proteoglycan 5 (GPC5) gene. Glypicans are a class of
heparan sulfate proteoglycans bound to the external surface
of plasma membranes that play an important role in the
control of cell division and growth regulation, but are also
implicated in brain pattering, synapse formation, axon regen-
eration and guidance, and are found in dense networks in
active MS plaques, where they may be involved in sequester-
ing pro-inflammatory chemokines (38–42). GPC5 is
expressed in neurons (43), and its interaction with growth
factors, chemokines and extracellular matrix proteins may
affect neuronal growth and repair (44). Recently, we reported
GPC5 allelic differences associated with extreme responses to
IFNb in MS patients (26). It is conceivable that a single gene
participates in both traits, conferring susceptibility and affect-
ing the phenotype (in this case, a pharmacogenomic response).
Alternatively, it is tantalizing to speculate that drug response
differences in MS reflect, at least in part, singular etiologies
characterized by different genetic backgrounds.
A second gene of interest emerging both from this study and
the IMSGC GWAS is PARK2 or Parkin (6q25.2–27), a com-
ponent of a multiprotein E3 ubiquitin ligase complex that med-
iates the targeting of substrate proteins for proteasomal
degradation. A 4.5 kb transcript is expressed in many human
tissues but is abundant in the brain. Mutations in this gene
cause a loss of function which may compromise the poly-
ubiquitination and proteasomal degradation of specific protein
substrates, potentially leading to their deleterious accumulation
in autosomal recessive juvenile-onset parkinsonism (37).
Parkinmutations also affect mitochondrial function and apopto-
sis in neuronal cells, processes of importance in MS pathogen-
esis (45). Interestingly, variations within this gene were found
to be associated with susceptibility to leprosy and other infec-
tious diseases (46,47). An important caveat, however, is the
very dense coverage of this gene in the SentrixwHumanHap550
BeadChip (455 SNPs), increasing the possibility for potential
type I errors. The signal inPARK2 did not survive the Sˇida´k cor-
rection, suggesting the need for a conservative interpretation of
its role in MS susceptibility.
The genes that we have associated with the MS phenotype
are related to a broad range of cellular functions, but we did
not find the expected high representation of genes mediating
immunological effector functions. One exception is the associ-
ation between NALp11 and the severity metric MSSS. NALPs
are implicated in the activation of proinflammatory caspases
via their involvement in multiprotein complexes called inflam-
masomes (48). It is striking that RELN (reelin), a gene also
implicated in susceptibility to schizophrenia, autism, bipolar
disorder, depression, and temporal lobe epilepsy (49–51),
shows significant association with age of onset in MS (i.e.
first clinical expression of disease). We speculate that the
observed effect on age of onset is related to the role of
reelin on neuronal survival (52) and layering of neurons in
the cerebral cortex and cerebellum, affecting perhaps the
threshold of neuronal plasticity required to avoid the clinical
manifestation of the neurological damage (53). The associ-
ations between NLGN1 (neuroligin 1), HIP2 (huntingtin inter-
acting protein 2) and CDH10 (cadherin 10) with T2 lesion load
and brain atrophy, respectively, are consistent with roles for
factors facilitating ‘homeostatic’ maintenance of brain func-
tion in disease.
Deconstructing the genetic events leading to MS will clarify
its pathogenesis and improve opportunities to treat, prevent
and cure this disease. This study increases the resolution of
the MS genomic map by updating the roster of candidate
disease susceptibility and progression loci. The GO
summary analysis reflects the compartmentalization of the
genetic involvement in the susceptibility versus the neurode-
generative phases of this disease.
MATERIALS AND METHODS
Study participants
The study cohort was ascertained through a prospective multi-
center effort initiated in 2003. Three MS clinical centers were
involved in patient enrollment and biological specimen collec-
tion using identical inclusion criteria, two in Europe (Vrije
Universiteit Medical Center, Amsterdam; and University
Table 5. Replication of GPC5
SNP Allele, location Wald Chi-square Adjusted odds ratio (95% CI)a Adj Trend Log P-value Adj Geno Log P-value
rs553717 G/A, exon 3 1.01 A/G, OR ¼ 1.12 (0.90–1.39) 0.50 0.22
rs9523762 G/A, intron 7-8 8.34 A/G, OR ¼ 1.25 (1.07–1.45) 2.42 1.82
rs9516129 C/T, intron 7-8 5.77 T/C, OR ¼ 1.23 (1.04–1.45) 1.79 1.66
aAdditive model, covariates included in the logistic regression model: Gender, HLA-DRB11501(presence/absence).
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Table 6. Top markers associated with the MS phenotype, 2Log10(P) 5.0
SNP Chrom Position GeneSymbol Alleles Minor allele
frequency
Adj Geno
Log P-value
Adj Trend
Log P-value
Age of onset
rs1386330 11 87459075 RAB38 C/T 0.13 5.82 6.66
rs7432623 3 176222035 NAALADL2 A/G 0.18 5.72 2.52
rs404694 16 78140299 MAF T/G 0.27 5.61 0.73
rs17157903 7 103221987 RELN C/T 0.14 4.06 5.49
rs2116078 8 73526543 KCNB2 T/G 0.48 5.00 5.48
rs1557351 18 52903312 WDR7 C/T 0.22 4.89 5.43
rs2842483 9 76135704 RFK T/C 0.29 4.57 5.32
rs3804281 6 41853967 FRS3 C/T 0.46 5.31 0.72
rs12047808 1 176200971 C1orf125 A/G 0.13 4.82 5.24
rs5997184 22 25873695 CRYBA4 C/T 0.09 5.20 2.01
rs4704970 5 155433570 SGCD A/G 0.20 3.59 5.13
rs1437898 2 133580362 FLJ34870 G/T 0.40 4.36 5.09
rs2803418 9 76138828 RFK T/G 0.26 4.37 5.08
rs868824 7 109985872 IMMP2L C/T 0.40 3.95 5.02
rs7914524 10 129994857 MKI67 C/T 0.17 5.01 3.19
MSSS
rs12553535 9 12902861 C9orf150 G/T 0.24 7.26 4.51
rs752092 15 99599457 CHSY1 C/T 0.37 5.84 1.69
rs12638253 3 158108793 FLJ16641 C/T 0.47 4.19 5.68
rs1478091 4 132148106 LOC132321 C/T 0.06 4.53 5.68
rs10936043 3 158179208 FLJ16641 A/G 0.46 4.16 5.66
rs8043243 15 99588976 CHSY1 C/T 0.42 5.53 2.34
rs2028455 18 46220003 C18orf24 A/G 0.31 5.47 3.44
rs299175 19 61005340 NALP11 C/T 0.46 4.28 5.37
rs10259085 7 7041671 C1GALT1 C/T 0.46 4.49 5.37
rs10518025 4 67893206 CENPC1 C/T 0.14 4.85 5.35
rs2035213 4 132145387 LOC132321 A/C 0.06 4.23 5.33
rs16925027 9 6968321 JMJD2C A/G 0.24 5.33 0.66
rs6941421 6 15197130 JARID2 C/T 0.39 4.56 5.24
rs7191888 16 72138559 C16orf47 A/G 0.17 4.20 5.23
rs180358 11 116104602 MGC13125 G/A 0.23 4.51 5.22
rs10243024 7 115940554 MET A/G 0.23 4.58 5.21
rs10516537 4 107985675 DKK2 A/C 0.15 5.10 3.77
rs337718 18 67925258 CBLN2 T/C 0.29 4.38 5.07
rs7253363 19 11543495 ACP5 G/T 0.05 4.66 5.05
rs12142240 1 46459321 LRRC41 C/T 0.29 4.52 5.00
rs7211577 17 14055005 COX10 A/G 0.49 4.96 5.00
Brain parenchymal volume
rs4866550 5 3361312 IRX1 C/T 0.32 6.06 2.09
rs10078091 5 25530762 CDH10 A/G 0.27 5.91 4.66
rs368380 20 14762090 C20orf133 C/T 0.33 5.73 1.47
rs4473631 4 174876499 MORF4 A/C 0.22 5.55 0.57
rs1869410 2 5207954 SOX11 C/T 0.28 5.40 3.70
rs261902 12 32367994 BICD1 T/C 0.16 4.42 5.36
rs11719646 3 56442731 CAST1 A/G 0.38 5.29 3.30
rs1354913 11 89794461 CHORDC1 A/G 0.18 5.23 0.16
rs13067869 3 175148379 NLGN1 G/T 0.07 5.20 4.83
rs9307252 4 102359544 PPP3CA C/T 0.14 5.18 4.16
rs9480865 6 109023266 FOXO3A C/T 0.16 4.52 5.19
rs9486902 6 108984745 FOXO3A C/T 0.16 4.52 5.12
rs1927457 10 30048669 SVIL C/T 0.31 4.69 5.11
rs716595 10 111996476 MXI1 A/G 0.08 3.81 5.10
rs11957313 5 169882972 KCNIP1 A/G 0.13 3.73 5.07
rs9319189 13 85516099 SLITRK6 A/G 0.35 5.01 2.54
rs10917727 1 160028398 CDCA1 C/T 0.47 5.00 4.28
T2 lesion load
rs12097667 1 94209 PLD5 A/C 0.15 6.38 0.73
rs1806468 7 212245 KIAA1706 C/T 0.11 5.65 4.13
rs146250 6 158286 GPR126 A/G 0.09 5.55 1.66
rs263153 6 279431 HIVEP2 C/A 0.09 5.55 1.74
rs6794496 3 422592 NPHP3 C/T 0.13 5.47 4.80
rs2602397 2 277843 CHRND C/T 0.45 4.48 5.39
rs6899560 6 429349 FUT9 A/G 0.05 5.26 2.56
rs2039485 14 232964 NUBPL C/T 0.22 4.63 5.22
rs305124 4 303690 HIP2 C/T 0.07 5.20 0.68
Continued
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Hospital Basel) and one in the USA (University of California
San Francisco). This study recruited patients of
northern-European ancestry, preferentially with a relapsing
onset of MS, although individuals with all clinical subtypes
of the disease participated, including clinically isolated syn-
drome (CIS), relapsing remitting MS (RRMS), secondary pro-
gressive MS (SPMS), primary progressive MS (PPMS) and
progressive relapsing MS (PRMS). CIS was defined as the
first well-established neurological event lasting 48 h, invol-
ving optic nerve, spinal cord, brainstem or cerebellum. In CIS
patients, the presence of two or more hyperintense lesions on a
T2-weighted magnetic resonance imaging (MRI) sequence
was also required for enrollment into the study. The diagnosis
of RRMS was made utilizing the new International Panel cri-
teria (54,55). SPMS was defined by 6 months of worsening
neurological disability not explained by clinical relapse.
PPMS was defined both by progressive clinical worsening
for more than 12 months from symptom onset without any
relapses, and abnormal cerebrospinal fluid as defined by the
presence of 2 oligoclonal bands or an elevated IgG index.
If acute relapses were superimposed on this steadily progress-
ive course, patients were considered to have PRMS. Individ-
uals were excluded if they had experienced a clinical relapse
or received treatment with glucocorticosteroids within the pre-
vious month of enrollment. The concomitant use of disease
modifying therapies for MS was permitted. For all subjects,
the expanded disability status scale (56) and MSSS (57)
scores were assessed, and brain MRI scans were performed
within 2 weeks of entry into the study. In this study, age of
onset was defined as the first episode of focal neurological
dysfunction suggestive of CNS demyelinating disease (17).
This information was obtained via individual recall and veri-
fied through review of medical records. The control group
consisted of unrelated individuals, primarily spouses/partners,
friends and other volunteers. Control subjects were of
northern-European ancestry and matched as a group, pro-
portionally with cases according to age (+5 years), gender.
A familial history or current diagnosis of MS as well as a
relation to another case or control subject were considered
exclusionary for this group. Protocols were approved by the
Table 6. Continued
SNP Chrom Position GeneSymbol Alleles Minor allele
frequency
Adj Geno
Log P-value
Adj Trend
Log P-value
rs6917747 6 430506 IGF2R A/G 0.15 4.72 5.17
rs11666377 19 74887 CPAMD8 C/T 0.14 4.42 5.15
rs12202350 6 98302 IGF2R C/T 0.09 5.10 4.71
rs6512158 19 405242 CPAMD8 A/C 0.14 4.29 5.02
Table 7. Gene ontology analysis
GO (Biological process) n Genes (observed) Genes
(expected)
Ratio
(O/E)
P-value
Susceptibility
CNS development 6 MOG, PARK2, SH3GL2, ZIC1, CHST9, JRKL 0.52 11.5 0.00001
Organ morphogenesis 5 SPRY2, CITED2, ABLIM1, NPR1, ZIC1 0.98 5.1 0.003
Antigen presentation (MHC
class I)
3 HLA-A, HLA-B, HLA-G 0.09 33.3 0.00009
Antigen presentation (MHC
class II)
3 HLA-DPB1, HLA-DQA2, HLA-DQB1 0.08 35.7 0.00006
MSSS
Protein amino acid N-linked
Glycosylation
2 FUT8, TM4SF4 0.15 13.3 0.009
Cellular respiration 2 ME3, COX10 0.15 13.3 0.009
Embryonic development 2 FUT8, KLF4 0.1 20.0 0.005
Age of onset
Cell adhesion 9 CDH12, DLG1, CNTN6, OPCML, PCDH10, TPBG, PPFIBP1,CASK PSCD1 3.3 2.8 0.005
Signal transduction 25 FRS3, RASSF8, PDZD8, CPE, DAPK1, DOCK1, EDNRB, DKK1, RASD2,
RAB38, RASGRP3, CNTN6, GRIK1, HTR7, KDR, OR51B6, OR51M1,
OR51I1, PDE4D, PDE6A, RGR, VIP, SPSB1, IRS2, PSCD1
16.1 1.6 0.009
CNS development 4 CNTN6, GRIK1, PBX1, PCP4 0.63 6.4 0.003
Excretion 3 VIP, NPHS2, KCNK5 0.22 13.6 0.001
Brain parenchymal volume
Glutamate signaling pathway 2 GRIN2A, HOMER2 0.07 28.6 0.002
T2 Lesion load
Calcium-mediated signaling 3 EGFR, PIP5K3, MCTP2 0.11 27.2 0.0002
G-protein signaling 3 DGKG, EDNRB, EGFR 0.29 10.3 0.003
Axon guidance 2 SLIT2, NRXN1 0.12 16.7 0.007
Hemopoiesis 3 JAG1, LRMP, BCL11A 0.44 6.8 0.009
Regulation of cell migration 2 JAG1, EGFR 0.13 15.4 0.008
Amino acid metabolism 5 EGFR, MSRA, SLC6A6, UBE1DC1, SLC7A5 1.06 4.7 0.004
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Committees on Human Research at all Institutions and
informed consent was obtained from all participants prior to
participation in the study.
Image acquisition
Brain MRI scans were performed on all cases upon entry into
the study in 1.5 (Europe) and 3 (US) Tesla instruments using
common sequences and protocols for data acquisition. MRIs
were analyzed centrally at the project-MRI Evaluation
Center (Basel) without the knowledge of disease subtype, dur-
ation or treatment history. Conventional spin echo,
T1-weighted images were acquired for 5 min following
administration of a single dose (0.1 mM/kg) of contrast agent
(TE/TR ¼ 8/467 ms, 256  256  44 matrix, 240  240 
132 FOV, NEX ¼ 1). Qualitative analysis for the presence
of gadolinium enhancement was performed on post-contrast
T1-weighted images. Brain lesions were identified and
marked by consensus reading on simultaneously viewed T2
long and proton density-weighted images. Additional evalu-
ations were done for new T2 lesions and volume of black
holes, volume of T2 and T1 gadolinium enhanced lesions.
The volumes were measured using an interactive digital analy-
sis program (AMIRA).
The SIENAX algorithm (an adaptation of SIENA—
Structural Image Evaluation using Normalization of
Atrophy—for cross-sectional measurements) was used to esti-
mate whole nBPV, normalized for subject head size (58,59).
SIENAX extracts brain and skull images from the single struc-
tural acquisition. The brain image is registered to a standard
space using the skull image to determine the registration
scaling. Tissue segmentation, with partial volume estimation,
is carried out to calculate total brain volume. SIENAX soft-
ware are freely available as part of the FMRIB Software
Library (www.fmrib.ox.ac.uk/fsl).
Genotyping, quality control and statistical analysis
Genotyping of the complete dataset was performed at the Illu-
mina facilities using the Sentrixw HumanHap550 BeadChip.
Sample success rate was 98.2% and the overall call rate was
99.85%. In addition to sample genotyping efficiency, a five-
point quality control procedure was implemented before
analysis, including assessment of marker allelic frequency,
Hardy–Weinberg equilibrium, gender consistency, reproduci-
bility and population genetic structure. Association analysis
was carried out on 551 642 SNPs in 978 cases and 883
controls.
DRB11501 genotyping was performed using a validated
gene-specific TaqMan assay designed to identify, specifically,
the presence or absence of DRB11501 and/or 1503 alleles.
An internal positive control (ß-globin) was included in each
well to confirm that the reaction amplified successfully. PCR
was carried out in a total volume of 10 ml, containing 20 ng
DNA, 1x TaqMan Universal PCR Master Mix (Applied Bio-
systems), 0.6mM DRB11501/1503 specific primers (forward
50;-ACG TTT CCT GTG GCA GCC TAA-30, reverse
50-TGC ACT GTG AAG CTC TCC ACA A-30), 0.3 mM
control primers (forward 50-ACT GGG CAT GTG GAG
ACA GAG AA-30, reverse 50-AGG TGA GCC AGG CCA
TCA CTA AA-30), 0.225 mM VIC-labeled DRB11501/1503
specific probe (50-AAC AGC CAG AAG GAC ATC CTG
GAG CA-30) and 0.025 mM 6FAM-labeled control probe
(50-TCT ACC CTT GGA CCC AGA GGT TCT TTG
AGT-30). Amplification was carried out in an ABI PRISM
7900HT Sequence Detection System (Applied Biosystems)
with an initial 958C for 10 min, followed by 50 cycles of
958C for 15 s and 628C for 1 min. Results were confirmed
with tagging SNP rs3135388 (60).
Two statistical methods were used to account for different
models of genetic effect (1): the genotype-based case–
control test for testing the dominant/additive/recessive allele
effects on disease (61), and (2) a linear trend test for additive
allelic effects on disease penetrance [Cochran–Armitage trend
test (62)], with an asymptotic x2 distribution (1 d.f.). In order
to address the problem of multiple testing, we implemented
the false discovery rate (FDR) method (63). Logistic
regression models were used to incorporate multiple covari-
ates in the analysis of the transformed data, including
gender, center of sample origin and DRB11501 status.
To correct for a potential bias towards detection of false-
positive associations in large genes, the Sˇida´k-corrected
minimum P-value (64) for each gene, adjusted for LD, was
obtained using the formula:
Pmin, corrected ¼ 12(12Pmin)Meff,
where Pmin is the minimum P-value obtained from the SNPs
tested within the gene under consideration, for association
with a particular phenotype using a particular statistical and
genetic model. Meff is the effective number of SNPs tested
within the gene, obtained by the method of Li and Ji (65),
which is based on the eigenvalues of the correlation matrix
(LD matrix) among the SNPs in the gene (66,67).
If the LD between every pair of SNPs tested within the gene
is zero, then Meff is equal to M, the actual number of SNPs
tested.
For the genotype–phenotype correlation analysis, four
different phenotypes were assessed: T2 lesion load, nBPV,
MSSS and age of onset. Covariates included in the model
were gender, center of sample origin, age onset, disease dur-
ation, treatment status and treatment duration. Transformation
of the phenotypic data (cube-root transformation for T2 lesion,
square-root transformation for MSSS and log transformation
for age of onset) was performed prior to data analysis in
order to meet the normality assumption for the regression
model. We also performed analyses separately at each site,
using the Fisher’s method to combine the P-values over sites.
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG Online.
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